XMD17-109

XMD17-109 is a novel, specific ERK-5 inhibitor, with an IC50 of 162 nM.

Product Specifications

CAS Number

[1435488-37-1]

UNSPSC

12352005

Hazard Statement

H315, H319

Target

ERK

Type

Reference compound

Related Pathways

MAPK/ERK Pathway; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/xmd17-109.html

Concentration

10mM

Purity

99.20

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1C2=C(C=CC=C2)N(C3CCCC3)C4=NC(NC5=C(OCC)C=C(C(N6CCC(N7CCN(C)CC7)CC6)=O)C=C5)=NC=C4N1C

Molecular Formula

C36H46N8O3

Molecular Weight

638.80

Precautions

H315, H319

References & Citations

[1]Deng X, et al. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6 (11H) -ones. Eur J Med Chem. 2013;70:758-67.|[2]Elkins, Jonathan M., et al. X-ray Crystal Structure of ERK5 (MAPK7) in Complex with a Specific Inhibitor. Journal of Medicinal Chemistry (2013), 56 (11), 4413-4421.|[3]Wilhelmsen K, et al. Extracellular signal-regulated kinase 5 promotes acute cellular and systemic inflammation. Sci Signal. 2015 Aug 25;8 (391) :ra86.